Business Context and Reporting Period
This Form 8-K Current Report was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on February 6, 2009. The filing discloses a private placement of equity securities to raise capital for working capital and general corporate purposes.
Key Financial Metrics
- Gross Proceeds Raised: $1,752,803
- Placement Agent Fees: $122,696 (paid to Merriman Curhan Ford and Co.)
- Net Proceeds: Approximately $1,630,107 (calculated as gross proceeds minus fees)
- Unit Price: $116.90 per unit
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, or cash flow from operations.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or current liquidity ratios.
Material Changes and Transaction Details
The company executed Purchase Agreements with a group of accredited investors. For every $116.90 invested, investors received:
- 100 shares of common stock (par value $0.0001).
- Series A Warrant: To purchase 58 shares at $1.87/share; exercisable after 6 months; 5-year term.
- Series B Warrant: To purchase 78 shares at $1.13/share; exercisable after 6 months; 3-year term.
- Series C Warrant: Issued for every 2 shares purchased via Series B exercise; to purchase 1 share at $1.94/share; exercisable after 6 months; 5-year term.
The offering relied on the Section 4(2) exemption from registration under federal securities laws.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the use of proceeds and future expectations. Management explicitly states that actual results could differ materially due to risks described in their Form 10-K. The company does not intend to update these forward-looking statements except as required by law. No specific financial guidance or revenue outlook was provided in this document.
Investor Verification Checklist
- Verify the exact number of units sold and total shares issued by reviewing Exhibit 10.1 (Purchase Agreement).
- Confirm the dilution impact of the Series A, B, and C warrants on existing shareholders.
- Review the company's most recent Form 10-K for current debt levels and liquidity status, as this 8-K does not provide them.
- Assess the company's cash burn rate to determine if the $1.63 million in net proceeds is sufficient for the stated working capital needs.